Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Immunic gets a "positive surprise" from lead asset trial

By: News Direct

--News Direct--

Immunic Inc (NASDAQ: IMUX) CEO Dr. Daniel Vitt speaks to Proactive following the release of data from the maintenance phase of its phase 2b CALDOSE-1 trial of lead asset vidofludimus calcium (IMU-838) in patients with moderate-to-severe ulcerative colitis (UC).

Vitt describes it as "wonderful data" that came as a "positive surprise."

Contact Details

Proactive United States

Proactive United States

+1 347-449-0879

action@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/immunic-gets-a-positive-surprise-from-lead-asset-trial-619463718

Recent Quotes

View More
Symbol Price Change (%)
AMZN  242.30
+3.00 (1.25%)
AAPL  263.00
+3.52 (1.36%)
AMD  245.04
+8.31 (3.51%)
BAC  53.65
+0.45 (0.85%)
GOOG  338.32
-0.21 (-0.06%)
META  709.20
-7.30 (-1.02%)
MSFT  428.75
-1.54 (-0.36%)
NVDA  187.26
-3.87 (-2.03%)
ORCL  166.39
+1.81 (1.10%)
TSLA  419.63
-10.78 (-2.50%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.